Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsKleinert, Robin D V
Brown, Richard J P
MetadataShow full item record
AbstractYellow fever virus (YFV) represents a re-emerging zoonotic pathogen, transmitted by mosquito vectors to humans from primate reservoirs. Sporadic outbreaks of YFV occur in endemic tropical regions, causing a viral hemorrhagic fever (VHF) associated with high mortality rates. Despite a highly effective vaccine, no antiviral treatments currently exist. Therefore, YFV represents a neglected tropical disease and is chronically understudied, with many aspects of YFV biology incompletely defined including host range, host-virus interactions and correlates of host immunity and pathogenicity. In this article, we review the current state of YFV research, focusing on the viral lifecycle, host responses to infection, species tropism and the success and associated limitations of the YFV-17D vaccine. In addition, we highlight the current lack of available treatments and use publicly available sequence and structural data to assess global patterns of YFV sequence diversity and identify potential drug targets. Finally, we discuss how technological advances, including real-time epidemiological monitoring of outbreaks using next-generation sequencing and CRISPR/Cas9 modification of vector species, could be utilized in future battles against this re-emerging pathogen which continues to cause devastating disease
CitationViruses. 2019 Oct 17;11(10). pii: v11100960. doi: 10.3390/v11100960.
AffiliationTWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection <i>In Vivo</i>.
- Authors: Douam F, Soto Albrecht YE, Hrebikova G, Sadimin E, Davidson C, Kotenko SV, Ploss A
- Issue date: 2017 Aug 15
- Vaccine and Wild-Type Strains of Yellow Fever Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune Responses.
- Authors: Fernandez-Garcia MD, Meertens L, Chazal M, Hafirassou ML, Dejarnac O, Zamborlini A, Despres P, Sauvonnet N, Arenzana-Seisdedos F, Jouvenet N, Amara A
- Issue date: 2016 Feb 9
- What Does the Future Hold for Yellow Fever Virus? (I).
- Authors: Klitting R, Gould EA, Paupy C, de Lamballerie X
- Issue date: 2018 Jun 8
- A mouse model for studying viscerotropic disease caused by yellow fever virus infection.
- Authors: Meier KC, Gardner CL, Khoretonenko MV, Klimstra WB, Ryman KD
- Issue date: 2009 Oct
- Host-Specific NS5 Ubiquitination Determines Yellow Fever Virus Tropism.
- Authors: Miorin L, Laurent-Rolle M, Pisanelli G, Co PH, Albrecht RA, García-Sastre A, Morrison J
- Issue date: 2019 Jul 15